Clinical Trial Update: Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 study investigating anti-MART-1 F5 cells combined with ALVAC MART-1 vaccine for advanced/metastatic melanoma was terminated; results were posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Skin Cancer

Drugs mentioned

• ALVAC MART-1 vaccine
• Anti-MART-1 F5 cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma, Skin Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-04-19